Under the leadership of Rob Michael, AbbVie continues to make tremendous progress in developing its immunology and ...
The Schwab U.S. Dividend Equity ETF is also one of the most well-diversified ETFs, with double-digit exposures to key sectors ...
Dr. Mehmet Oz has pledged to eliminate his conflicts of interest before he would helm the Centers for Medicare and Medicaid ...
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.
Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...
AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results